三诺生物传感股份有限公司 关于回购公司部分股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 | 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-039 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 1、公司未在下列期间内回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会规定和深圳证券交易所规定的其他情形。 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2023 年 8 月 7 日召开第 五届董事会第四次会议和第五届监事会第四次会议，审议并通过《关于回购公司 部分股份方案的议案》，独立董事就本次回购事项发表了同意的独立意见，同意 公司使用自有资金不低于人民币 8,000 万元且不超过人民币 15,000 万元（均含本 数），以集中竞价交易的方式回购公司部分社会公众股份，用于员工持股计划或 者股权激励。回购价格不超过人民币 35.00 元/股（含），实施期限自董事会审议 通 ...

中信证券股份有限公司 关于三诺生物传感股份有限公司 2023年度持续督导培训情况的报告 深圳证券交易所： （七）培训对象：公司实际控制人、董事、监事、高级管理人员及其他相关 人员等 （八）培训内容： 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）根据《深圳证 券交易所上市公司自律监管指引第 13 号——保荐业务》（以下简称"保荐工作指 引"）对三诺生物传感股份有限公司（以下简称"三诺生物"、"公司"）进行了 2023 年度持续督导培训，报告如下： 一、本次持续督导培训的基本情况 （一）保荐机构：中信证券股份有限公司 （二）保荐代表人：邵才捷、王栋 （三）协办人：彭博 （四）培训时间：2024 年 4 月 17 日 （五）培训地点：湖南省长沙市三诺生物会议室现场和远程视频会议 （六）培训人员：邵才捷 （本页无正文，为《中信证券股份有限公司关于三诺生物传感股份有限公司 2023 保荐机构通过现场授课的方式对公司实际控制人、董事、监事、高级管理人 员及其他相关人员进行了培训，本次培训重点介绍了我国资本市场近况、新公司 法调整的重点事项、新"国九条"解析、上市公司被采取监管措施的典型案例及 关注要点等专题 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6][27]. Core Insights - The company achieved a revenue of 40.59 billion RMB in 2023, a year-on-year increase of 3%, while the net profit attributable to the parent company was 2.84 billion RMB, a decrease of 36% [23]. - The blood glucose monitoring business showed stable growth, with a revenue of 28.73 billion RMB, up 6% year-on-year, and an overall gross margin of 54.39%, an increase of 1.2 percentage points [23]. - The company has successfully registered its Continuous Glucose Monitoring (CGM) products in seven regions globally, indicating strong potential for future growth [23]. Summary by Sections Financial Performance - Revenue for 2022 was 28.14 billion RMB, with a growth rate of 19.15%, while the projected revenue for 2024 is 49.02 billion RMB, reflecting a growth rate of 20.78% [9]. - The net profit for 2022 was 431 million RMB, with a significant increase of 300.56% compared to the previous year, but a projected decrease of 36.31% in 2023 [9]. - The diluted earnings per share (EPS) for 2024 is expected to be 0.872 RMB, with a projected growth rate of 73.11% [9]. Market Position - The company has a comprehensive domestic distribution network, covering over 3,500 hospitals and more than 220,000 pharmacies, while also expanding its presence in international markets [23]. - The company’s products are registered in 85 countries, showcasing its global reach and potential for recovery in sales [23]. Research and Development - The company invested 3.56 billion RMB in R&D in 2023, accounting for 8.78% of total revenue, indicating a commitment to innovation [23]. - The third-generation direct electronic transfer technology developed by the company has shown industry-leading performance metrics [23].

| --- | --- | --- | --- | --- | |----------------------|-------|---------------------------------|-------------|-------| | [Table_MainFinance] | 2023A | | 2024E 2025E | 2026E | | 营业收入(百万元) | | 4058.79 4631.30 5276.73 5996.64 | | | | 收入增长率% | | 2.69 14.11 13.94 13.64 | | | | 归母净利润（百万元） | | 284.40 443.60 560.77 703.20 | | | | 利润增速% | | -36.31 55.98 26.41 25.40 | | | | 毛利率% | | 54.06 56.43 56.44 56.71 | | | | 摊薄 EPS(元) | | 0.50 0.79 0.99 1.25 | | | | PE | | 45.97 29.47 23.31 18.59 | | | | PB | | 4.25 3.75 3.23 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][3]. Core Views - The company is positioned as a leading domestic player in the Continuous Glucose Monitoring (CGM) market, with expected sales growth following the launch of its CGM products in 2023, projecting sales revenue of approximately 800 million in 2023 and a target of 300 to 500 million in 2024 [1][3]. - The company has been developing CGM products since 2008, and the recent approval of its new products is anticipated to drive performance growth [1]. - The company has achieved significant international milestones, including CE certification for its CGM products in 2023 and plans to submit an FDA application in 2024, indicating potential for overseas market expansion [11]. Financial Summary - The company reported revenues of 4.059 billion and a net profit of 284 million for 2023, with a year-over-year revenue growth of 2.69% [10]. - The forecast for net profit is adjusted to 445 million for 2024 and 525 million for 2025, reflecting a decrease of 17.6% and 21.6% respectively from previous estimates [3]. - The company’s revenue from blood glucose monitoring (BGM) reached 2.873 billion in 2023, with a year-over-year growth of 6.21% [19]. Growth Projections - The company expects to achieve profitability by 2025, with the second-generation CGM products anticipated to enhance its product lineup [1]. - The projected revenue growth rates for the next few years are 12.78% for 2024, 13.79% for 2025, and 14.68% for 2026 [12]. - The company’s earnings per share (EPS) is forecasted to increase from 0.50 in 2023 to 1.11 by 2026 [12].

Investment Rating - The report maintains a "Buy" rating for the company, citing confidence in the future growth of its CGM (Continuous Glucose Monitoring) products [13] Core Views - The company achieved revenue of 4.059 billion yuan in 2023, a year-on-year increase of 2.69%, and net profit attributable to the parent company of 284.4 million yuan, a year-on-year decrease of 36.31% [2] - The overseas subsidiary Trividia, which was impacted by U.S. healthcare policy changes, showed significant improvement in the second half of 2023 and is expected to turn profitable in 2024, reducing impairment risks [2] - The company's CGM product achieved sales exceeding 100 million yuan in its first year of launch, with strong potential for domestic and international market expansion [2] - The company's traditional BGM (Blood Glucose Monitoring) business remains stable, with a projected revenue growth of 10-15% in 2024 [2] - The company's cost control measures have been effective, with reductions in sales, management, and R&D expense ratios in Q1 2024 [2] Financial Performance and Forecasts - Revenue is expected to grow from 4.059 billion yuan in 2023 to 6.093 billion yuan in 2026, with a compound annual growth rate (CAGR) of 14.06% to 15.23% [2] - Net profit attributable to the parent company is forecasted to increase from 284.4 million yuan in 2023 to 621.61 million yuan in 2026, with a CAGR of 44.96% to 18.68% [2] - EPS (Earnings Per Share) is projected to rise from 0.50 yuan in 2023 to 1.10 yuan in 2026 [2] - The company's P/E ratio is expected to decrease from 45.97 in 2023 to 21.03 in 2026, reflecting improved profitability [2] CGM Product Development - The company's CGM product, utilizing third-generation direct electron transfer technology, has achieved MARD (Mean Absolute Relative Difference) values of 8.71% and 7.45%, positioning it as a leader in the industry [2] - The company has obtained registrations for its CGM product in seven regions, including the UK and Italy, and is progressing with clinical trials in the U.S., with FDA approval expected by Q2-Q3 2025 [2] Traditional Business and Cost Management - The company's traditional BGM business is expected to grow steadily, with a focus on higher-margin products [2] - In Q1 2024, the company reduced its sales, management, and R&D expense ratios to 24.66%, 6.49%, and 9.43%, respectively, reflecting effective cost management [2] Valuation and Market Position - The company's current market capitalization corresponds to a P/E ratio of 32/25/21X for 2024-2026, indicating a favorable valuation relative to its growth prospects [2] - The company's CGM product is well-positioned to capture market share in both domestic and international markets, leveraging its established BGM market presence and product advantages [2]

敬请参阅末页重要声明及评级说明 证券研究报告 我们增加对 2026 年业绩预测，预计 2024-2026 年公司收入分别为 47.11 亿元、54.95 亿元和 63.84 亿元，收入增速分别为 16.1%、16.7% 和 16.2%，2024-2026 年归母净利润分别实现 4.50 亿元、5.76 亿元和 7.20 亿元，增速分别为 58.3%、28.0%和 24.9%，2024-2026 年 EPS 预计分别为 0.80 元、1.02 元和 1.28 元，对应 2024-2026 年的 PE 分别 为 29x、23x 和 18x，公司深耕血糖监测领域，BGM 业务稳定增长，CGM 国内初步开始放量，即将实现盈利，海外市场预计在 2025 年美国市场 上市，长期成长性高，维持"买入"评级。 | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------|-------------|------- ...

SINOCARE SOCIAL RESPONSIBILITY REPORT 2023 三诺生物 企业社会责任报告 2023 年度 目 录 CONTENTS | 报告说明 | 03 恪守对员工的承诺 | | --- | --- | | | 员工规模与结构 | | 数说2023 | 企业文化 | | 董事长致辞 | 人才引进 | | | 人才发展 | | 走进三诺 | 薪酬福利 | | | 沟通渠道 | | 公司简介 | 员工健康与安全 | | 公司大事记 | | | 公司品牌传播 | | | 企业荣誉 可持续发展战略 | | | | 业绩回报 | 02 恪守对用户的承诺 04 恪守对股东、合作伙伴和社会的承诺 2024年社会责任承诺 公司治理结构 合作伙伴 社会公益 科技创新与发展 零售渠道 医院渠道 基层医疗 线上平台 国际市场 智能制造与绿色生产 质量体系 数智化未来 三诺全球 《三诺生物传感股份有限公司2023年度社会责任报告》（以下简称"本报告"）是三诺生物传感股份有限公司 及控股子公司2023年度履行社会责任的整体报告，展现了公司在环境、社会和公司治理等责任领域的实践和绩 效，反映了公司在回馈股东、赋 ...

三诺生物传感股份有限公司 2023年度募集资金存放与使用情况的专项报告 三诺生物传感股份有限公司（以下简称"公司"）根据中国证监会《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、 《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等法律、法规及相关格式指引的规定， 现将公司 2023 年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）募集资金金额及到账时间 1、2018年重组配套募集资金基本情况 1、2018年重组配套募集资金以前年度使用金额情况 2023 年度以前实际使用募集资金 448,838,573.30 元，截至 2022 年 12 月 31 日，募集资金专户实际余额为 53,275,581.13 元。 | 项目 | 金额（单位：元） | | --- | --- | | 募集资金总额 | 502,649,986.28 | | 减：各项发行费用 | 16,737,999.73 | | 募集资金净额 | 485,911,986.55 | | 减：置换前期自筹资金投入 | 18,02 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2023-023 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届监事会第九次会议 于 2024 年 4 月 24 日（星期三）下午 14 时在公司会议室以现场方式召开。本次 会议的通知已于 2024 年 4 月 14 日通过书面或电子邮件方式送达全体监事。应出 席本次会议的监事 3 人，实际出席本次会议的监事 3 人，分别为欧阳柏伸先生、 陈春耕先生和黄绍波先生。会议由监事会主席欧阳柏伸先生召集并主持，公司董 事会秘书郑霁耘女士列席了会议。会议的召集、召开符合《公司法》及《公司章 程》、《公司监事会议事规则》的规定。 二、会议审议情况 经与会监事认真审议，本次会议以现场表决方式通过如下决议： （一）审议并通过《关于〈公司 2023 年监事会工作报告〉的议案》 2023 年，公司监事会严格按照《公司法》、《证券法》、《深圳证券 ...